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The Hippocratic and the principle of beneficence require that doctors should always act in the 
patient’s best interest. However, once the ‘doctor’ puts on the hat of a ‘doctor-investigator’ by 
involving in clinical trials, the responsibility to safeguard the interests of the patient is no longer 
a priority. This is because the interest or intent of the doctor-investigator is different from that of 
the doctor who offers medical treatment solely in the best interests of patients. Instead, there are 
many interests of doctor-investigators, which include financial incentives in return for recruiting 
patients as research subjects. When there is a conflict between the financial interests of doctors in 
recruiting patients and patients’ best interests, ethical challenges to the integrity of 
doctor-investigators may arise in making decision which is not bias. Hence, the objective of this 
paper is to discuss about conflict of interests between the doctor-investigator incentives to recruit 
and the doctor-investigator’s duty to keep the patients’ best interest. A qualitative methodology 
has been used in the process of writing this conceptual paper. The findings show that incentives 
gained by doctor-investigators in return for recruiting patients violate the principle of ethics 
because of the conflict of interests bearing in mind that the Hippocratic and the principle of 
beneficence require doctors to act in the patients’ best interest. 
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It is pertinent to note from the very beginning that recruiting humans as research subjects is 
important in clinical trials for the development of medical science. Unless an adequate number of 
participants is entered, the trial will not be able to answer the questions about benefit and risk. 
Therefore, there is a great pressure to recruit an adequate number of participants and to do so as 
quickly as possible. Likewise, the process to recruit humans as research subjects is not an easy 
thing. It is a problem often faced by the drug company wishing to test new drugs. In 2001, the 
Centre Watch reported that more than 85% of completed clinical trials experienced delay in the 
recruitment process, while 34% were also delayed for more than a month (Smith, 2008). As such, 
drug companies are 'forced' to make doctors their target for patient recruitment as research 
subjects. In return, the doctor-investigators are given incentives for each patient they successfully 
recruit (Gatter, 2006). When these doctor-investigators are also a patient’s doctor, there is a direct 
conflict of interest between the doctor-investigator’s incentives to recruit and the 
doctor-investigator’s duty to keep the patient’s best interest in mind (Sandhya Srinivasan, 2010). 
Where there is a conflict of interest, ethical challenges to the integrity of doctor-investigators will 
arise. 
 
Conflict of interest in clinical trial may exist when a doctor accepts a fee, gift or other incentive 
for finding and recruiting research subjects, especially if the research subject is his or her patient 
(College of Physicians and Surgeons of British Columbia, 2009). Some have defined conflict of 
interest as a situation in which the self-interest of the individual is in conflict with an obligation 
(Khushf & Gifford, 1998). Thompson (1993) has defined a conflict of interest as situations that 
cause conflicts when a decision is made to give priority to the acquisition of secondary 
importance such as financial income overcome such primary importance welfare of patients. 
Therefore, it can be said that a conflict of interest generally occurs when a person is entrusted to 
act or make decisions on behalf of others. In clinical trials, conflict of interest cannot be avoided 
as doctor-investigators are the one who is responsible to determine whether patients should 
participate in clinical trials as research subjects (Lo et al, 2000). The Hippocratic and the 
principle of beneficence require that doctors should always act in the patient’s best interest. 
However, when there is a conflict between the financial interests of the doctor-investigators in 
recruiting patients and patients’ best interests, ethical challenges to the integrity of 
doctor-investigators may arise in making decision when these doctor-investigators are also a 
patient’s doctor. Hence, the objective of this paper is to discuss about conflict of interest between 
the doctor-investigator’s incentives to recruit and duty to keep the patient’s best interest. A 
qualitative methodology has been used in the process of writing of this conceptual paper. 
 
1.3 The Causes of Conflict of Interests 
 
In general, medical codes of ethics across the world prohibit doctors to put their financial 
interests above the interests of their patients. For example, the American Medical Association’s 
Code of Medical Ethics specifies that: “Under no circumstances may physicians place their own 
financial interest above the welfare of their patients”. In Malaysia, the Code of Professional 
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Conduct adopted by the Malaysia Medical Council states that: “A prescribing practitioner should 
not only choose but also be seen to be choosing the drug or appliance which, in his independent 
professional judgment, and having due regard to economy, will best serve the medical interests 
of his patient. Practitioners should therefore avoid accepting any pecuniary or material 
inducement which might compromise, or be regarded by others as likely to compromise, the 
independent exercise of their professional judgment in prescribing matters. … It is improper for 
an individual practitioner to accept from a pharmaceutical firm monetary gifts or loans or 
expensive items of equipment for his personal use”. However, when it comes to rewards 
particularly in the form of ‘generous money’, anyone including doctor-investigators will deviate 
from these codes of ethics.  
 
Incentives in the form of payment accepted which generally exceeds patients’ expenses incurred 
by doctor-investigators lead them to enroll inappropriate participants. According to Foster (2003), 
a doctor may receive $3000 per recruit or higher and a quota of 30 patients may be called for in 
the study design. A study has shown that there are doctor-investigators who recommend trial 
drugs to patients by participating in clinical trials although the patients are likely to be better 
treated with existing treatments or no treatment (Shimm & Spece, 1991). There are also studies 
showing that doctor-investigators do not care about the inclusion and exclusion criteria 
established by the research protocol by recruiting patients who had no connection with the illness 
thus posing a danger to the safety of life of their patients. In fact, there are also 
doctor-investigators who commit fraud, falsifying recruit records solely to earn more income 
(Gatter, 2006; Lemmens & Miller, 2003; Caulfield & Griener, 2002).  
 
Furthermore, money can also interfere with the researcher’s ability to promote the rights and 
welfare of human subjects. A doctor-researcher with strong financial or personal interests in 
recruiting human subjects for a clinical trial may oversell the trial to his patients or take other 
steps to compromise the informed consent process (Shamoo & Resnik, 2003). The existence of a 
doctor-patient relationship also indirectly leads the patients to believe and feel confident that the 
invitation to participate in the trial is for their best interest. In addition, the borne illness makes 
patients have to rely on doctor-investigators to decide whether to enroll in the trial making them 
easy prey to be exploited as research subjects. This seems to be true by virtue of Paragraph 26 of 
the World Medical Association Declaration of Helsinki which states: “When seeking informed 
consent for participation in a research study the physician should be particularly cautious if the 
potential subject is in a dependent relationship with the physician or may consent under duress. 
In such situations the informed consent should be sought by an appropriately qualified individual 
who is completely independent of this relationship”. In fact, it is well established that the 
doctor-patient relationship is generally one of dependence. This is true in Malaysia. As 
mentioned earlier, the Malaysian society, especially the patients place great trust on their doctors. 
As such, doctors do not disclose full information to them. A study by Yuhanif, Anisah & Zaki 
Morad (2014) revealed that doctor-investigators fail to disclose full information to patients. 
Instead, doctor-investigators only disclosed information which they thought were necessary for 
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the patients to know. The study also showed that there were doctor-investigators who did not 
disclose information at all to their patients.  
In Malaysia, there is no study that has been conducted on conflict of interest of 
doctor-investigators. However, this does not mean that there is no such problem in the country. In 
support of this view, a reference can be made to the points put forward by the former Chairman 
of Malaysian Research Ethics Committees Dato’ Dr. Zaki Morad Mohamed Zahir (personal 
communication, 1 January 2015). He stated that: “Konflik kepentingan memang wujud di 
kalangan doktor-penyelidik di Malaysia antaranya adalah melalui bayaran yang diterima 
daripada pihak industri sebagai balasan merekrut pesakit ... by right doktor-penyelidik kena 
bagitau pesakit tentang perkara ini tapi banyak orang (doktor-penyelidik) tak bagi tau.” This 
opinion is also shared by the former Director of Clinical Research Centre Ministry of Health Dr. 
Lim Teck Onn (2008) in his paper titled, “Case studies and ethical issues in clinical trial” which 
was presented at the Good Clinical Practice Workshop held by the Sultanah Bahiyah Hospital 
Alor Setar on the 12 to 14 August 2008. He stated that, “Conflict of interests is extremely 
common, in fact conflict of interests is unavoidable”. Indeed, it is undeniable that the 
doctor-investigators should be given compensation for their time, expertise and effort to do 
research. One could argue, however that the incentives in the form of generous payment are 
intended to do more than merely compensate doctors for their effort (DeRenzo, 2000). As such, 
money or reward given by drug companies to doctors for recruiting patients into a study or trial 
is considered unethical practice (College of Physicians and Surgeons of British Columbia, 2009).  
 
1.4 Law Relating to Disclosure of Conflict of Interests 
 
Where conflict of interest cannot be avoided, the usual remedy is disclosure. The Declaration of 
Helsinki explicitly requires doctors to fully disclose information of all their relevant financial 
conflict of interest to the patient. Article 26 states that: “In medical research involving human 
subjects capable of giving informed consent, each potential subject must be adequately informed 
of the aims, methods, sources of funding, any possible conflicts of interest, institutional 
affiliations of the researcher, the anticipated benefits and potential risks of the study and the 
discomfort it may entail, post-study provisions and any other relevant aspects of the study”. 
Nevertheless, generally patients are not told that the 'doctor' will be paid by the drug company 
for entering them into a study (Harper & Reuter, 2009). The absence of federal requirements on 
doctor-investigators or institutions to disclose financial conflict of interest to patients (Kim et al, 
2004) makes things worse. To put it simply, the disclosure of information by doctor-investigators 
on relevant conflict of interest is not a legal requirement. Therefore, it is not surprising that the 
Institutional Review Boards (IRBs) do not require doctor-investigators to disclose information 
on the ‘payment transactions’ during the informed consent process. In fact, there are IRBs who 
think it is a private matter between doctor-investigators and sponsors (Roizen, 1988). However, 
there is a precedent in tort law for suing doctor-investigators or institutions for insufficient 
disclosure of conflicts (Moore v. Regents of University of California 793 P.2d 479 (CA, 1990), 
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cert. denied 112 S. Ct. 2967 (1992); Grimes v, Kennedy Krieger 782 A.2d 807 (MD, 2001)). This 
is because the law of negligence holds doctor-investigators liable for failing short of the 
customary standard in informing patients or subjects about the potential risks of a particular 
intervention. It is the duty of the doctor-investigators to provide full information to subjects to 
get consent. 
 
In Malaysia, until today there is no case law decided by the courts on the conflict of interests. In 
fact, the only guidelines that are related to clinical trials is the Malaysian Guidelines for Good 
Clinical Practice which also does not outline any provisions relating to the duty of doctors to 
disclose information on the conflict of interests to patients. This raises concerns to various parties. 
In fact, concerns to this matter was voiced out by the former Director General of Health Tan Sri 
Dr Mohd Ismail Merican at the Ethical Issues in Clinical Research Conference on 22 December 
2005 saying that: “As the benefits offered by health research are becoming obvious, so too are 
the concerns they raised in terms of the ethical, legal and social issues with regard to the 
participation of human subjects …”. Also, a Malaysian local newspaper, the New Strait Times 
(2002) has reported that: “Eyeing the expanding market for clinical research in the region, 
Malaysia is trying to position itself as an ideal place for pharmaceutical majors to conduct 
clinical trials. But critics worry about weak safeguards and poor enforceability of exiting 
regulation”. So, the only way for patient to know whether doctor-investigators have conflict of 
interest is to ask the doctor-investigators. Nonetheless, it is impossible for this to happen, in view 
of the attitude of the Malaysian society where patients put high hope on doctors.  
 
Likewise, there have been efforts or measures taken by the government to enforce guidelines on 
clinical trials. For example, the Control of Drugs and Cosmetics Regulations 1984 (Revised 2006) 
states that: “The Director of Pharmaceutical Services may issue written directives or guidelines 
to any person or group of persons as he thinks necessary for the better carrying out of the 
provisions of these Regulations and which in particular relate to clinical trials”. However, it is 
important to note that these regulations only exist in the form of directives issued by an 
administrator. Hence, the regulations are weak and can be disputed in terms of their legal aspects 
as compared to a legislation or an Act passed by the Parliament or the Legislative Assembly 
which has to go through a fairly rigorous process. As such, it is a high time to impose a duty on 
the doctor-investigators to disclose information related to conflict of interest to safeguard the 
patients’ welfare. Henceforth, the authors humbly believe that Malaysia should learn from 
Singapore and adopt a model to formulate regulations governing clinical trials in the country 
which could be incorporated under the Medicines Act giving such regulations a force of law. 
This would allow doctor-investigators to be punished if in case they contravene or fail to comply 
with the Act (regulations). In Singapore, they have Medicines (Clinical Trials) Regulations which 
have been incorporated under the Medicines Act (Chapter 176, Sections 18 and 74). For instance, 
section 20 provides that doctor-investigators are prohibited from having any directly or indirectly 
financial interest in the trial.  
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Indeed, incentives to doctor-investigators in return for recruiting patients violate the principle of 
ethics as doctor-investigators cannot put their personal or financial interests above the interests of 
patients. However, this is not an easy thing to do because when confronted with generous money 
then anyone would be influenced. As such, when faced with the problem of conflict of interest, a 
doctor-investigator must be honest with patients by disclosing related information and recruiting 
only a qualified patient as the research subject. This is because the doctor-patient relationship 
which is based on trust and dependency creates an unusually high danger of exploitation and 
abuse. In fact, doctor-investigators must also be honest with themselves as medical code of ethics 
clearly prohibits them to put their personal interests above the interests of their patients. This is 
so because doctor-investigators’ financial conflict of interest have the potential to undermine this 
trust. When there is no trust in the doctor-patient relationship, then there is no guarantee of 
continuity in the progress of clinical trials as there would be no participation by patients. It is 
indeed a matter of balancing between these two conflicting interests. Hence, it is inevitable that 
Malaysia should indeed learn from the Singapore as a model to formulate its own laws dealing 
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